2024
Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis
Squires P, Puckett J, Ryland K, Kamal-Bahl S, Raut M, Doshi J, Huntington S. Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis. Clinical Lymphoma Myeloma & Leukemia 2024, 24: e350-e358.e1. PMID: 39034204, DOI: 10.1016/j.clml.2024.05.023.Peer-Reviewed Original ResearchR/R MCLOverall survivalTreatment patternsRelapsed/refractory mantle cell lymphomaReal-world treatment patternsBruton tyrosine kinase inhibitorCovalent Bruton tyrosine kinase inhibitorMantle cell lymphomaTyrosine kinase inhibitorsDevelopment of novel therapeuticsMCL patientsCell lymphomaThird-lineRetrospective studyTreatment initiationResponse durationAdverse eventsElderly patientsKinase inhibitorsPatient subpopulationsPatientsAll-causeNovel therapeuticsEconomic burdenSurvival
2023
Healthcare Resource Utilization and Costs Among Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients: A Retrospective Cohort Study Using Contemporary US Claims
Huntington S, Chang H, Fu A, Loefgren C, Lu X. Healthcare Resource Utilization and Costs Among Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients: A Retrospective Cohort Study Using Contemporary US Claims. Blood 2023, 142: 2348. DOI: 10.1182/blood-2023-181909.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationHealthcare resource utilizationAcute myeloid leukemia patientsRetrospective cohort studyIndex dateMyeloid leukemia patientsAML patientsAML diagnosisR patientsDiagnosis codesEconomic burdenPPPM costsCohort studyContinuous enrollmentND patientsLeukemia patientsMedical costsLarge US administrative claims databaseRefractory acute myeloid leukemia patientsHigher healthcare resource utilizationUS administrative claims databaseMore outpatient encountersNon-HSCT patientsNon-transplant recipientsOlder AML patients
2021
Treatment patterns, economic burden, and overall survival in US Medicare Advantage beneficiaries newly diagnosed with acute myeloid leukemia (AML) in 2015–2020
Huntington SF, Ingham MP, Okonkwo L, Singh A, Wang R, Ammann EM. Treatment patterns, economic burden, and overall survival in US Medicare Advantage beneficiaries newly diagnosed with acute myeloid leukemia (AML) in 2015–2020. Leukemia & Lymphoma 2021, 63: 1180-1190. PMID: 34913805, DOI: 10.1080/10428194.2021.2012666.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaOverall survivalMedicare Advantage beneficiariesMyeloid leukemiaEconomic burdenFirst-line treatment choiceMedian overall survivalMedicare Advantage patientsUnmet medical needSupportive careAgent monotherapyAML patientsClinical outcomesContemporary cohortTreatment patternsAdvantage patientsTreatment choicePatient managementMedical needHealthcare expendituresPatientsOlder adultsLeukemiaPresent studySurvival